1
|
Golz C, Kilcher G, Gerlach M, Hägerbäumer M, Peter KA, Blozik E. Translation and Psychometric Testing of the Hägerbäumer Presenteeism Scale in English. J Occup Rehabil 2024:10.1007/s10926-024-10174-2. [PMID: 38466556 DOI: 10.1007/s10926-024-10174-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 01/27/2024] [Indexed: 03/13/2024]
Abstract
PURPOSE Interest in presenteeism has increased in research. Presenteeism is a behaviour of going to work despite illness. It has been predominantly measured using single items, which introduce limitations to validity. To overcome these limitations, Hägerbäumer developed a German multi-item presenteeism scale. METHODS The aim of the study was to provide an English translation and psychometric testing of the scale. This was conducted in two phases with native English-speaking employed adults. Phase 1 includes translation and cognitive debriefing, phase 2 testing construct validity and internal consistency reliability. RESULTS Cognitive debriefing with 10 employees revealed no problems with understanding or answering the translated items. In total, 487 employed adults participated in the study, of which data from 287 were included in the analysis. For structural validity, the goodness-of-fit indicators all reached their thresholds (TLI = 0.98, CFI = 0.99, RMSEA = 0.07, SRMR = 0.02). The scale does not show differences between sexes and age groups but between sectors (F6,70.95 = 5.53, p < 0.001). The internal consistency reliability was satisfactory with α = 0.89 (CI 95%, 0.87-0.91). CONCLUSION The translated multidimensional scale for measuring presenteeism at the behavioural level demonstrated good psychometric properties in an initial validation. Further psychometric testing is required before using this scale in cross-national comparison in research and international companies.
Collapse
Affiliation(s)
- Christoph Golz
- Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland.
| | - G Kilcher
- Department of Health Services Research, SWICA Healthcare Organisation, Winterthur, Switzerland
| | - M Gerlach
- Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland
| | - M Hägerbäumer
- Department of Psychology, EURO-FH University of Applied Sciences, Hamburg, Germany
| | - K A Peter
- Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland
| | - E Blozik
- Department of Health Services Research, SWICA Healthcare Organisation, Winterthur, Switzerland
- Institute of Primary Care, University and University Hospital of Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Abstract
Due to their unusual electronic structure, the biradical m-benzyne, C6H4, and its cation are of considerable interest in chemistry. Here, the photoion mass-selected threshold photoelectron spectrum of the m-benzyne biradical is presented. An adiabatic ionization energy of 8.65 ± 0.015 eV is derived, while a vibrational progression of 0.10 eV is assigned to the ν9+ ring breathing mode, in excellent agreement with computations. The experimental spectrum was reproduced well by Franck-Condon spectral modeling of the 2A1 ← X 1A1 transition, in which the cation retains a monocyclic C6 framework. The energetically close-lying bicyclic 2A2 cation state exhibits low Franck-Condon factors, due to the large change in geometry, and thus cannot be observed.
Collapse
Affiliation(s)
- M Gerlach
- Institute of Physical and Theoretical Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - E Karaev
- Institute of Physical and Theoretical Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - D Schaffner
- Institute of Physical and Theoretical Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - P Hemberger
- Laboratory for Synchrotron Radiation and Femtochemistry, Paul Scherrer Institut (PSI), CH-5232 Villigen-PSI, Switzerland
| | - I Fischer
- Institute of Physical and Theoretical Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
| |
Collapse
|
3
|
Gerlach M, Schmitt S, Cyprys P, Kasper MA, Mai I, Vermeer MH, Horwitz SM, Fingerle-Rowson G, Vogl A, Schumacher D, Helma-Smets J. TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00604-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Tini E, Smigielski L, Romanos M, Wewetzer C, Karwautz A, Reitzle K, Correll C, Plener P, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Banaschewski T, Hellenschmidt T, Imgart H, Kaess M, Kölch M, Renner T, Reuter-Dang S, Rexroth C, Schulte-Körne G, Theisen F, Fekete S, Taurines R, Gerlach M, Egberts K, Walitza S. Therapeutic drug monitoring of sertraline in pediatric population: A
naturalistic study with insights into the clinical response of
obsessive-compulsive disorder. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- E. Tini
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - L. Smigielski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - M. Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - C. Wewetzer
- Kliniken der Stadt Köln GmbH, Clinic for Child and Adolescent
Psychiatry Holweide, Children's Hospital Amsterdamer Straße,
Cologne, Germany
| | - A. Karwautz
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - K. Reitzle
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C.U. Correll
- Department of Child and Adolescent Psychiatry, Charité
Universitätsmedizin Berlin, Berlin, Germany
- The Zucker Hillside Hospital, Department of Psychiatry, Northwell
Health, Glen Oaks, NY, USA
- Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell, Department of Psychiatry and Molecular Medicine,
Hempstead, NY, USA
| | - P.L. Plener
- Department of Child and Adolescent Psychiatry/Psychotherapy,
University Hospital Ulm, Ulm, Germany
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - U. Malzahn
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
| | - P. Heuschmann
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
- Institute of Clinical Epidemiology and Biometry, University of
Wuerzburg, Germany
| | - S. Unterecker
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - M. Scherf-Clavel
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - H. Rock
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - G. Antony
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - W. Briegel
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Leopoldina Hospital, Schweinfurt, Germany
| | - C. Fleischhaker
- Department of Child and Adolescent Psychiatry and Psychotherapy,
University Medical Center Freiburg, Freiburg, Germany
| | - T. Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg
University, Mannheim, Germany
| | - T. Hellenschmidt
- Department of Child and Adolescent Psychiatry, Psychotherapy and
Psychosomatic medicine, Vivantes Clinic Berlin Neukölln, Berlin,
Germany
| | - H. Imgart
- Parkland-Clinic, Clinic for Psychosomatics and Psychotherapy, academic
teaching hospital for the University Gießen, Bad Wildungen,
Germany
| | - M. Kaess
- Clinic for Child and Adolescent Psychiatry, Center for Psychosocial
Medicine, University Hospital Heidelberg, Heidelberg, Germany
- University Hospital of Child and Adolescent Psychiatry and
Psychotherapy, University of Bern, Bern, Switzerland
| | - M. Kölch
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Brandenburg Medical School Brandenburg, Neuruppin, Germany
- Department of Child and Adolescent Psychiatry, Neurology,
Psychosomatics, and Psychotherapy, University Medical Center Rostock, Rostock,
Germany
| | - T. Renner
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University Hospital of Psychiatry and Psychotherapy Tuebingen,
Center of Mental Health Tuebingen, Germany
| | - S.Y. Reuter-Dang
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C. Rexroth
- Clinic for Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University of Regensburg at the Regensburg District Hospital,
medbo KU, Regensburg, Germany
| | - G. Schulte-Körne
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Ludwig-Maximilians-University (LMU) Hospital, Munich,
Germany
| | - F. Theisen
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Herz-Jesu-Krankenhaus gGmbH, Fulda, Germany
| | - S. Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - R. Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - M. Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - K.M. Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - S. Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
- Zurich Center for Integrative Human Physiology, University of Zurich,
Zürich, Switzerland
- Neuroscience Center Zurich, University of Zurich and ETH, Zurich,
Switzerland
| |
Collapse
|
5
|
Wesner K, Hiemke C, Bergemann N, Gerlach M, Havemann-Reinecke U, Lense X, Riemer T, Schoretsanitis G, Uhr M, Zernig G, Gründer G, Hart X. The therapeutic reference range for olanzapine revised – how
to combine old and new findings. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- K. Wesner
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
Germany
| | - C. Hiemke
- University Medical Center of Mainz, Department of Psychiatry and
Psychotherapy and Institute of Clinical Chemistry and Laboratory Medicine,
Mainz, Germany
| | - N. Bergemann
- AMEOS Clinic for Psychiatry, Psychotherapy and Psychosomatics, Bad
Salzuflen, Germany
| | - M. Gerlach
- Division of Clinical Neurochemistry, Department of Psychiatry and
Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - U. Havemann-Reinecke
- Department of Psychiatry and Psychosomatics, University of
Göttingen, Göttingen, Germany
| | - X.M. Lense
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
Germany
| | - T.G. Riemer
- Berlin Institute of Health, Institute of Clinical Pharmacology and
Toxicology, Charité – Medical University of Berlin, Free
University of Berlin, Humboldt University of Berlin, Berlin,
Germany
| | - G. Schoretsanitis
- University of Zurich, Department of Psychiatry, Psychotherapy and
Psychosomatics, Zurich, Switzerland
| | - M. Uhr
- Clinical Laboratory, Max Planck Institute of Psychiatry, Munich,
Germany
| | - G. Zernig
- Experimental Psychiatry Unit, Department of Psychiatry and
Psychotherapy, Medical University of Innsbruck, Innsbruck, and Private Practice
for Psychotherapy and Court-Certified Witness, Hall in Tirol,
Austria
| | - G. Gründer
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
Germany
| | - X.M. Hart
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
Germany
| |
Collapse
|
6
|
Eichentopf L, Hiemke C, Conca A, Engelmann J, Gerlach M, Havemann-Reinecke U, Hefner G, Florio V, Kuzin M, Lieb K, Reis M, Riemer T, Seretti A, Schoretsanitis G, Zernig G, Gründer G, Hart XM. Escitalopram: Drug monitoring for dose titration? Systematic
literature review on the therapeutic and the dose-related reference
range. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- L. Eichentopf
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, Heidelberg University, Mannheim,
Germany
| | - C. Hiemke
- Institute of Clinical Chemistry and Laboratory Medicine- University
Medical Center of Mainz, Department of Psychiatry and Psychotherapy, Mainz,
Germany
| | - A. Conca
- Central Hospital- Sanitary Agency of South Tyrol, Department of
Psychiatry, Bolzano, Italy
| | - J. Engelmann
- Department of Psychiatry and Psychotherapy, Johannes Gutenberg
University Medical Center Mainz, Mainz, Germany
| | - M. Gerlach
- University Hospital Würzburg, Department of Child and
Adolescent Psychiatry- Psychosomatics and Psychotherapy, Würzburg,
Germany
| | - U. Havemann-Reinecke
- University of Göttingen, Department of Psychiatry and
Psychosomatics, Göttingen, Germany
| | - G. Hefner
- Vitos Clinic for Forensic Psychiatry, Forensic Psychiatry, Eltville,
Germany
| | - V. Florio
- Vitos Clinic for Forensic Psychiatry, Forensic Psychiatry, Eltville,
Germany
- Department of Psychiatry, Comprensorio Sanitario di Bolzano, Bolzano,
Italy
| | - M. Kuzin
- Clienia Schlössli AG- Academic Teaching Hospital of the
University of Zurich, Psychiatric and Psychotherapeutic Private Clinic, Oetwil
am See, Switzerland
| | - K. Lieb
- Department of Psychiatry and Psychotherapy, University Medical Center
Mainz, Mainz, Germany
| | - M. Reis
- Department of Biomedical And Clinical Sciences, Linköping
University, Linköping, Sweden
- Department of Clinical Chemistry and Pharmacology, Skåne
University hospital, Lund, Sweden
| | - T.G. Riemer
- Berlin Institute of Health, Institute of Clinical Pharmacology and
Toxicology, Charité - Universitätsmedizin Berlin, Freie
Universität Berlin, Humboldt-Universität zu Berlin, Berlin,
Germany
| | - A. Seretti
- Department of Biomedical and Neuromotor Sciences, University of
Bologna, Bologna, Italy
| | - G. Schoretsanitis
- Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of
Psychiatry, University of Zurich, Zurich, Switzerland
| | - G. Zernig
- Medical University of Innsbruck, Department of Psychiatry, Innsbruck,
Austria
- Private Practice for Psychotherapy and Court-Certified Witness, Private
Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol,
Austria
| | - G. Gründer
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, Heidelberg University, Mannheim,
Germany
| | - X. M. Hart
- Central Institute of Mental Health, Department of Molecular
Neuroimaging, Medical Faculty Mannheim, Heidelberg University, Mannheim,
Germany
| |
Collapse
|
7
|
Fekete S, Güntzel T, Egberts K, Geissler J, Neubert A, Gerlach M, Romanos M, Taurines R. Serious adverse drug reactions to antipsychotics in children and
adolescents with multiple disabilities: Avoidability and potential cost savings
by Therapeutic Drug Monitoring. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- S. Fekete
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
| | - T. Güntzel
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
| | - K. Egberts
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
- AGNP-Work group «Therapeutic Drug
Monitoring»
- Competence network for Therapeutic Drug Monitoring in child and
adolescent psychiatry
| | - J. Geissler
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
| | - A. Neubert
- Department of Experimental and Clinical Pharmacology and Toxicology,
Friedrich Alexander University Erlangen-Nuernberg, Erlangen,
Germany
| | - M. Gerlach
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
- AGNP-Work group «Therapeutic Drug
Monitoring»
- Competence network for Therapeutic Drug Monitoring in child and
adolescent psychiatry
| | - M. Romanos
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group ‘Child and Adolescent
Psychopharmacology’
- AGNP-Work group «Therapeutic Drug
Monitoring»
| | - R. Taurines
- University Hospital of Wuerzburg, Center of Mental Health, Department
of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Wuerzburg,
Germany
- AGNP-Work group «Therapeutic Drug
Monitoring»
| |
Collapse
|
8
|
Smigielski L, Tini E, Romanos M, Wewetzer C, Karwautz A, Reitzle K, Correll C, Plener P, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Banaschewski T, Hellenschmidt T, Imgart H, Kaess M, Kölch M, Renner T, Reuter-Dang S, Rexroth C, Schulte-Körne G, Theisen F, Fekete S, Taurines R, Gerlach M, Egberts K, Walitza S. Therapeutic drug monitoring of mirtazapine in children and
adolescents: Analysis of dose, steady-state concentration and responsiveness in
a naturalistic clinical setting. PHARMACOPSYCHIATRY 2022. [DOI: 10.1055/s-0042-1747661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- L. Smigielski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - E. Tini
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
| | - M. Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - C. Wewetzer
- Kliniken der Stadt Köln GmbH, Clinic for Child and Adolescent
Psychiatry Holweide, Children's Hospital Amsterdamer Straße,
Cologne, Germany
| | - A. Karwautz
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - K. Reitzle
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C.U. Correll
- Department of Child and Adolescent Psychiatry, Charité
Universitätsmedizin Berlin, Berlin, Germany
- The Zucker Hillside Hospital, Department of Psychiatry, Northwell
Health, Glen Oaks, NY, USA
- Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell, Department of Psychiatry and Molecular Medicine,
Hempstead, NY, USA
| | - P.L. Plener
- Department of Child and Adolescent Psychiatry/Psychotherapy,
University Hospital Ulm, Ulm, Germany
- Department of Child and Adolescent Psychiatry, Medical University
Vienna, Vienna, Austria
| | - U. Malzahn
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
| | - P. Heuschmann
- Clinical Trial Center Wuerzburg, University Hospital Wuerzburg,
Wuerzburg, Germany
- Institute of Clinical Epidemiology and Biometry, University of
Wuerzburg, Germany
| | - S. Unterecker
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - M. Scherf-Clavel
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of
Mental Health, University Hospital Wuerzburg, Wuerzburg, Germany
| | - H. Rock
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - G. Antony
- Central Information Office, Department of Neurology, Philipps
University of Marburg, Marburg, Germany
| | - W. Briegel
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Leopoldina Hospital, Schweinfurt, Germany
| | - C. Fleischhaker
- Department of Child and Adolescent Psychiatry and Psychotherapy,
University Medical Center Freiburg, Freiburg, Germany
| | - T. Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg
University, Mannheim, Germany
| | - T. Hellenschmidt
- Department of Child and Adolescent Psychiatry, Psychotherapy and
Psychosomatic medicine, Vivantes Clinic Berlin Neukölln, Berlin,
Germany
| | - H. Imgart
- Parkland-Clinic, Clinic for Psychosomatics and Psychotherapy, academic
teaching hospital for the University Gießen, Bad Wildungen,
Germany
| | - M. Kaess
- Clinic for Child and Adolescent Psychiatry, Center for Psychosocial
Medicine, University Hospital Heidelberg, Heidelberg, Germany
- University Hospital of Child and Adolescent Psychiatry and
Psychotherapy, University of Bern, Bern, Switzerland
| | - M. Kölch
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Brandenburg Medical School Brandenburg, Neuruppin, Germany
- Department of Child and Adolescent Psychiatry, Neurology,
Psychosomatics, and Psychotherapy, University Medical Center Rostock, Rostock,
Germany
| | - T. Renner
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University Hospital of Psychiatry and Psychotherapy Tuebingen,
Center of Mental Health Tuebingen, Germany
| | - S.Y. Reuter-Dang
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
- Specialist practice and Medical Care Center for Child and Adolescent
Psychiatry Munich, Munich, Germany
| | - C. Rexroth
- Clinic for Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University of Regensburg at the Regensburg District Hospital,
medbo KU, Regensburg, Germany
| | - G. Schulte-Körne
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Ludwig-Maximilians-University (LMU) Hospital, Munich,
Germany
| | - F. Theisen
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Herz-Jesu-Krankenhaus gGmbH, Fulda, Germany
| | - S. Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - R. Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - M. Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - K.M. Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg,
Wuerzburg, Germany
| | - S. Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy,
Psychiatric University Hospital Zurich, University of Zurich, Zürich,
Switzerland
- Zurich Center for Integrative Human Physiology, University of Zurich,
Zürich, Switzerland
- Neuroscience Center Zurich, University of Zurich and ETH, Zurich,
Switzerland
| |
Collapse
|
9
|
Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm (Vienna) 2022; 129:689-701. [PMID: 35303169 PMCID: PMC9188514 DOI: 10.1007/s00702-022-02485-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Accepted: 02/24/2022] [Indexed: 01/31/2023]
Abstract
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RISam) concentration was found (rs = 0.49, p = 0.001) with variation in dose explaining 24% (rs2 = 0.240) of the variability in serum concentrations. While the RISam concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RISam concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RISam was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.
Collapse
Affiliation(s)
- R Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - S Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - A Preuss-Wiedenhoff
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - A Warnke
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - C Wewetzer
- Clinic for Child and Adolescent Psychiatry and Psychotherapy, Clinics of the City Cologne GmbH, Cologne, Germany
| | - P Plener
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany.,Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria
| | - R Burger
- Department of Psychiatry, Psychosomatics and Psychotherapy, Laboratory for Therapeutic Drug Monitoring, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany
| | - K M Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany.
| |
Collapse
|
10
|
Eastman K, Gerlach M, Piec I, Greeves J, Fraser W. Effectiveness of parathyroid hormone (PTH) analogues on fracture healing: a meta-analysis. Osteoporos Int 2021; 32:1531-1546. [PMID: 33559713 DOI: 10.1007/s00198-021-05847-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Accepted: 01/12/2021] [Indexed: 12/21/2022]
Abstract
UNLABELLED This meta-analysis evaluated the evidence for the use of parathyroid hormone (PTH) analogues to improve fracture healing. Eligible studies were prospective randomised controlled trials of adults with acute fractures treated with a PTH analogue. PTH improved functional outcomes but did not affect fracture healing rate or reduce pain. PURPOSE This meta-analysis evaluated the evidence of parathyroid hormone (PTH) analogues in fracture healing. The use of PTH analogues to prevent osteoporotic fractures is well investigated, and studies are emerging on extended indications. One such indication receiving increasing attention is the effect of PTH in fracture healing; however, the overall degree of efficacy remains inconclusive. METHODS A systematic electronic database search of MEDLINE, EMBASE and the Cochrane Library was conducted for relevant articles in August 2019 with no date restrictions. Randomised controlled trials of adults with acute fractures treated with a PTH analogue were included. PTH was compared with a comparator intervention, placebo or no treatment. RESULTS PTH analogue treatment improved functional outcomes in a range of fracture types but did not affect the fracture healing rate or reduce pain. Most trials included in this review were in elderly patients with osteoporosis. There was no evidence that PTH treatment caused harm or impeded fracture healing. CONCLUSIONS Meta-analysis of published data supports the use of PTH analogues to improve functional outcomes but not fracture healing rate or pain for different fracture types. The evidence for PTH analogue use in fracture healing is less clear in younger, non-osteoporotic patient populations. Trial design was heterogeneous and of limited quality, justifying further original trials.
Collapse
Affiliation(s)
- K Eastman
- Norwich Medical School, University of East Anglia, Norwich, UK.
| | - M Gerlach
- Norfolk and Norwich University Hospital, Norwich, UK
| | - I Piec
- Norwich Medical School, University of East Anglia, Norwich, UK
| | - J Greeves
- Norwich Medical School, University of East Anglia, Norwich, UK
- Department of Army Health and Performance Research, Andover, Hampshire, UK
| | - W Fraser
- Norwich Medical School, University of East Anglia, Norwich, UK
| |
Collapse
|
11
|
Fekete S, Egberts K, Preissler T, Wewetzer C, Mehler-Wex C, Romanos M, Gerlach M. Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride. Eur J Clin Pharmacol 2021; 77:1257. [PMID: 34047799 PMCID: PMC8496611 DOI: 10.1007/s00228-021-03159-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Stefanie Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany.
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany.
| | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
| | - T Preissler
- Department of Child and Adolescent Psychiatry and Psychotherapy, Kepler University Clinics GmbH, Linz, Austria
| | - C Wewetzer
- Clinic for Child and Adolescent Psychiatry and Psychotherapy, Clinics of the City Cologne GmbH, Cologne, Germany
| | - C Mehler-Wex
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany
- HEMERA Private Hospital for Mental Health, Adolescents and Young Adults, Bad Kissingen, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
- Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP)-Work Group "Kinder- Und Jugendpsychiatrische Pharmakologie", Psychotherapie Und Psychosomatik, Kliniken Für Kinder- Und Jugendpsychiatrie, Vivantes Klinikum Im Friedrichshain, 1. Vorsitzender Prof. Dr. med. M. KölchVivantes Klinikum Neukölln, Landsberger Allee 49, 10249, Berlin, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP E.V.), Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre forMental Health, University Hospital ofWürzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany
| |
Collapse
|
12
|
Gerlach M, Wolff S, Ludwig S, Schäfer W, Keiner B, Roth NJ, Widmer E. Rapid SARS-CoV-2 inactivation by commonly available chemicals on inanimate surfaces. J Hosp Infect 2020; 106:633-634. [PMID: 32916211 PMCID: PMC7480442 DOI: 10.1016/j.jhin.2020.09.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 09/01/2020] [Indexed: 12/23/2022]
Affiliation(s)
- M Gerlach
- CSL Behring GmbH, Global Pathogen Safety, Marburg, Germany.
| | - S Wolff
- CSL Behring GmbH, Global Pathogen Safety, Marburg, Germany
| | - S Ludwig
- Westfaelische Wilhelms-University Muenster, Institute of Virology, Muenster, Germany
| | - W Schäfer
- CSL Behring GmbH, Global Pathogen Safety, Marburg, Germany
| | - B Keiner
- CSL Behring GmbH, Global Pathogen Safety, Marburg, Germany
| | - N J Roth
- CSL Behring GmbH, Global Pathogen Safety, Marburg, Germany
| | - E Widmer
- CSL Behring GmbH, Global Pathogen Safety, Marburg, Germany
| |
Collapse
|
13
|
Egberts K, Plener P, Fekete S, Taurines R, Gerlach M, Romanos M. 6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0040-1710114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- K Egberts
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - P Plener
- Department of Child and Adolescent Psychiatry, Medical University Vienna
| | - S Fekete
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - R Taurines
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - M Gerlach
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | - M Romanos
- Department of child and adolescent psychiatry, University Hospital Wuerzburg
| | | |
Collapse
|
14
|
Fekete S, Scherf-Clavel M, Gerlach M, Romanos M, Kittel-Schneider S, Unterecker S, Egberts K. 8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0040-1710116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- S Fekete
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| | - M Scherf-Clavel
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
| | - M Gerlach
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| | - M Romanos
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| | - S Kittel-Schneider
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
| | - S Unterecker
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
| | - K Egberts
- Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg
| |
Collapse
|
15
|
Fekete S, Scherf-Clavel M, Gerlach M, Romanos M, Deckert J, Menke A, Egberts K, Unterecker S. Investigation of metabolite to parent compound ratios of venlafaxine and risperidone in minors. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3403046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- S Fekete
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Scherf-Clavel
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Gerlach
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - J Deckert
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - A Menke
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - K Egberts
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - S Unterecker
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| |
Collapse
|
16
|
Radtke F, Holweck J, Geissler J, Strork T, Drepper C, Fouskova Z, Gerlach M, Fischer M, Romanos M. Olfactory function, transcranial sonography and fear generalization in patients with 22q11.2 deletion syndrome along the lifespan. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0039-3402995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- F Radtke
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - J Holweck
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - J Geissler
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - T Strork
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - C Drepper
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - Z Fouskova
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Gerlach
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Fischer
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| | - M Romanos
- Universitätsklinikum Würzburg, Zentrum für Psychische Gesundheit, Germany
| |
Collapse
|
17
|
Gerlach M, Brinkmann H, Pasura L, Schwickert A, Henrich W, Braun T. Fetales Mikrobiom – Ist bereits eine intrauterine Besiedlung möglich? Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- M Gerlach
- Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Deutschland
| | - H Brinkmann
- Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Deutschland
| | - L Pasura
- Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Deutschland
| | - A Schwickert
- Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Deutschland
| | - W Henrich
- Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Deutschland
| | - T Braun
- Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Deutschland
| |
Collapse
|
18
|
Wohkittel C, Romanos M, Högger P, Gerlach M. Influence of saliva pH-value on the ratio of amphetamine saliva to serum concentration. PHARMACOPSYCHIATRY 2018. [DOI: 10.1055/s-0038-1649542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- C Wohkittel
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Würzburg, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Würzburg, Germany
| | - P Högger
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Würzburg, Würzburg, Germany
| |
Collapse
|
19
|
Egberts K, Dang SY, Plener P, Karwautz A, Taurines R, Romanos M, Gerlach M. Therapeutic Drug Monitoring in children and adolescents – looking 10 years back and forward. PHARMACOPSYCHIATRY 2018. [DOI: 10.1055/s-0038-1649528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - SY Dang
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
| | - P Plener
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany
- Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - A Karwautz
- Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - R Taurines
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
- Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V
| |
Collapse
|
20
|
Gerlach M, Föhre B, Keh D, Riess H, Falke K, Gerlach H. Global and Extended Coagulation Monitoring during Extracorporeal Lung Assist with Heparin-Coated Systems in ARDS Patients. Int J Artif Organs 2018. [DOI: 10.1177/039139889702000107] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Heparin-coated systems for extracorporeal lung-assist (ECLA) were developed to reduce hemorrhagic risk by lowering the systemic heparinization, monitored by global tests, e.g. activated coagulation time (ACT) and activated partial thromboplastin time (APTT). Since this strategy gives no insight into procoagulant states, five ARDS patients receiving ECLA with heparin-coated systems were investivated for changes in coagulation using both global and extended tests. During ECLA onset the APTT and ACT were within or near normal ranges, platelets decreased 76.5% within 48h, fibrinogen decreased 28.7%, thrombin-antithrombin-III complexes were elevated before ECLA (53 μg/L), but demonstrated an additional peak (238 μg/L), plasminogen-activator-inhibitor-1 increased 12-fold, and the C1-inhibitor dropped 14.1%. In conclusion, after the onset of ECLA from a previous prethrombotic state, the precoagulant, anticoagulant, fibrinolytic and complement systems were activated in a similar way to that reported for non-heparinized systems with high-dose heparin. This was however only monitored by an extended test panel which was unable to predict thromboembolic events during ECLA.
Collapse
Affiliation(s)
- M. Gerlach
- Clinic for Anesthesiology and Critical Care Medicine, Virchow-Klinikum of the Humboldt University, Berlin - Germany
| | - B. Föhre
- Clinic for Anesthesiology and Critical Care Medicine, Virchow-Klinikum of the Humboldt University, Berlin - Germany
| | - D. Keh
- Clinic for Anesthesiology and Critical Care Medicine, Virchow-Klinikum of the Humboldt University, Berlin - Germany
| | - H. Riess
- Medical Clinic, Department of Hematology and Hemostaseology, Virchow-Klinikum of the Humboldt University, Berlin - Germany
| | - K.J. Falke
- Clinic for Anesthesiology and Critical Care Medicine, Virchow-Klinikum of the Humboldt University, Berlin - Germany
| | - H. Gerlach
- Clinic for Anesthesiology and Critical Care Medicine, Virchow-Klinikum of the Humboldt University, Berlin - Germany
| |
Collapse
|
21
|
Keh D, Gerlach M, Kürer I, Falke K, Gerlach H. Reduction of Platelet Trapping in Membrane Oxygenators by Transmembraneous Application of Gaseous Nitric Oxide. Int J Artif Organs 2018. [DOI: 10.1177/039139889601900506] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Bleeding during extracorporeal circulation (ECC) is often induced and/or aggravated by thrombocytopenia due to platelet-trapping in hollow fiber membrane oxygenators (HFMO). Nitric oxide (NO) has platelet anti-aggregating and dis-aggregating properties. In a paired system we tested whether gaseous NO, added to the gas compartment of one of two parallel running heparin-bonded HFMO attenuated platelet-trapping. Platelet consumption was markedly reduced in the NO-treated HFMO. These data strongly indicate that the application of gaseous NO could prove a new therapeutical approach to reduce bleeding during ECC, serving as a new way of preventing platelet loss, thus reducing the need for high systemic heparinization.
Collapse
Affiliation(s)
- D. Keh
- Dept. of Anaesthesiology and Intensive Care Medicine, Virchow Clinic, Humboldt University, Berlin - Germany
| | - M. Gerlach
- Dept. of Anaesthesiology and Intensive Care Medicine, Virchow Clinic, Humboldt University, Berlin - Germany
| | - I. Kürer
- Dept. of Anaesthesiology and Intensive Care Medicine, Virchow Clinic, Humboldt University, Berlin - Germany
| | - K.J. Falke
- Dept. of Anaesthesiology and Intensive Care Medicine, Virchow Clinic, Humboldt University, Berlin - Germany
| | - H. Gerlach
- Dept. of Anaesthesiology and Intensive Care Medicine, Virchow Clinic, Humboldt University, Berlin - Germany
| |
Collapse
|
22
|
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51:e1. [PMID: 29390205 DOI: 10.1055/s-0037-1600991] [Citation(s) in RCA: 100] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- C Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany.,Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany
| | - N Bergemann
- Kitzberg Hospitals, Center for Psychosomatic Medicine and Psychotherapy, Bad Mergentheim, Germany
| | - H W Clement
- Department of Child and Adolescent Psychiatry, University of Freiburg, Freiburg, Germany
| | - A Conca
- Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
| | - J Deckert
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - K Domschke
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | | | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - C Greiner
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - G Gründer
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - E Haen
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - U Havemann-Reinecke
- Department of Psychiatry and Psychosomatics, University of Göttingen, Göttingen, Germany
| | - G Hefner
- Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany
| | - R Helmer
- Center of Epilepsy, Bielefeld, Germany
| | - G Janssen
- Medical Laboratory Stein, Limbach Group, Mönchengladbach, Germany
| | - E Jaquenoud
- Psychiatric Hospital, Königsfelden, Brugg, Aargau, Switzerland
| | - G Laux
- Institute of Psychological Medicine, Haag in Oberbayern, Germany
| | - T Messer
- Danuviuskliniken, Psychiatric Hospital, Pfaffenhofen, Germany
| | - R Mössner
- Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
| | - M J Müller
- Psychiatric Hospitals Oberberggruppe, Berlin, Germany
| | - M Paulzen
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - B Pfuhlmann
- Psychiatric Hospital Weisser Hirsch, Dresden, Germany
| | - P Riederer
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - A Saria
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria
| | - B Schoppek
- kbo-Isar-Amper Klinikum München-Ost, Psychiatric Hospital, Munich-Haar, Germany
| | | | - M Schwarz
- Department of Laboratory Medicine, Ludwig Maximilian University, Munich, Germany
| | - M Silva Gracia
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - B Stegmann
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - W Steimer
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany
| | - J C Stingl
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - M Uhr
- Max Planck Institute of Psychiatry, Munich, Germany
| | - S Ulrich
- Aristo Pharma GmbH, Berlin, Germany
| | - S Unterecker
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | | | - G Zernig
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria.,Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria
| | - G Zurek
- Medical Laboratory Bremen, Bremen, Germany
| | - P Baumann
- Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland
| |
Collapse
|
23
|
Gerlach M, Banaschewski T, Warnke A, Rothenberger A. Ist ein Parkinson-Syndrom als Spätfolge einer Methylphenidatbehandlung im Kindesalter möglich? ACTA ACUST UNITED AC 2018. [DOI: 10.1055/s-0038-1624376] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
ZusammenfassungDie Wirksamkeit von Psychostimulanzien wie Methylphenidat (MPH) in der Therapie von Kindern und Jugendlichen mit einer Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) wurde in zahlreichen klinischen Studien belegt. Bislang wurde bei sachgemäßer Anwendung von keinen schwerwiegenden Nebenwirkungen berichtet. Dennoch gibt es immer wieder Bedenken, dass diese Arzneimittel auch bei sachgemäßer Anwendung eine Abhängigkeit auslösen und möglicherweise Spätfolgen auf die Gehirnentwicklung haben könnten. Durch diese Mutmaßungen, die, wie im Folgenden detailliert dargelegt, durch die bisher vorliegenden wissenschaftlichen Befunde nicht gerechtfertigt sind, sind nicht nur Kinderärzte sowie Kinder- und Jugendpsychiater stark verunsichert, sondern vor allem auch die ADHS-Patienten und deren Angehörigen. Die bisher vorliegenden tierexperimentellen Ergebnisse rechtfertigen auf keinen Fall Spekulationen hinsichtlich irgendwelcher Spätfolgen. Aufgrund methodischer Grenzen lässt sich aus den Ergebnissen nicht schlussfolgern, dass MPH das Auswachsen dopaminerger Axone unterdrückt und/oder eine reduzierte Bildung von dopaminergen Synapsen hervorruft. Tierexperimentelle und klinische Untersuchungen lassen dagegen den Schluss zu, dass die Gefahr, nach einer MPH-Therapie im Kindes-und Jugendalter in späteren Jahren an einem Parkinson-Syndrom zu erkranken, mit höchster Wahrscheinlichkeit als nicht gegeben angesehen werden kann.
Collapse
|
24
|
Hackstein H, Möller A, Gerlach M, Sachs U, Bein G. Prospective quality control study of a novel gravity-driven whole blood separation system suitable for humanitarian crises. Vox Sang 2017; 112:806-809. [PMID: 28952151 DOI: 10.1111/vox.12595] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 07/15/2017] [Accepted: 08/29/2017] [Indexed: 11/28/2022]
Abstract
Centrifugation-based whole blood (WB) separation represents the worldwide standard but it depends on electricity and infrastructure. We have prospectively evaluated a novel hollow-fibre WB separation system that does not require manual priming or blood flow regulation (n = 29). RBC units contained sufficient Hb (50·4 g ± 4·3), low leucocytes (90 000 ± 0·008), exhibited low haemolysis (0·57% ± 0·49) and robust ATP content (51·47% ± 8·2) after 43 days storage. Plasma units contained low leucocytes and mean coagulation factor activities for FV, FVIII and FXI were 47%, 90% and 68%, respectively. RBC met quality specifications but plasma units exhibited reduced FV and FXI activity.
Collapse
Affiliation(s)
- H Hackstein
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Giessen, Germany
| | - A Möller
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Giessen, Germany
| | - M Gerlach
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Giessen, Germany
| | - U Sachs
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Giessen, Germany
| | - G Bein
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Giessen, Germany
| |
Collapse
|
25
|
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2017; 51:9-62. [PMID: 28910830 DOI: 10.1055/s-0043-116492] [Citation(s) in RCA: 533] [Impact Index Per Article: 76.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.
Collapse
Affiliation(s)
- C Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany.,Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany
| | - N Bergemann
- Kitzberg Hospitals, Center for Psychosomatic Medicine and Psychotherapy, Bad Mergentheim, Germany
| | - H W Clement
- Department of Child and Adolescent Psychiatry, University of Freiburg, Freiburg, Germany
| | - A Conca
- Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
| | - J Deckert
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - K Domschke
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | | | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - C Greiner
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - G Gründer
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - E Haen
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - U Havemann-Reinecke
- Department of Psychiatry and Psychosomatics, University of Göttingen, Göttingen, Germany
| | - G Hefner
- Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany
| | - R Helmer
- Center of Epilepsy, Bielefeld, Germany
| | - G Janssen
- Medical Laboratory Stein, Limbach Group, Mönchengladbach, Germany
| | - E Jaquenoud
- Psychiatric Hospital, Königsfelden, Brugg, Aargau, Switzerland
| | - G Laux
- Institute of Psychological Medicine, Haag in Oberbayern, Germany
| | - T Messer
- Danuviuskliniken, Psychiatric Hospital, Pfaffenhofen, Germany
| | - R Mössner
- Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
| | - M J Müller
- Psychiatric Hospitals Oberberggruppe, Berlin, Germany
| | - M Paulzen
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - B Pfuhlmann
- Psychiatric Hospital Weisser Hirsch, Dresden, Germany
| | - P Riederer
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - A Saria
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria
| | - B Schoppek
- kbo-Isar-Amper Klinikum München-Ost, Psychiatric Hospital, Munich-Haar, Germany
| | | | - M Schwarz
- Department of Laboratory Medicine, Ludwig Maximilian University, Munich, Germany
| | - M Silva Gracia
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - B Stegmann
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - W Steimer
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany
| | - J C Stingl
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - M Uhr
- Max Planck Institute of Psychiatry, Munich, Germany
| | - S Ulrich
- Aristo Pharma GmbH, Berlin, Germany
| | - S Unterecker
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | | | - G Zernig
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria.,Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria
| | - G Zurek
- Medical Laboratory Bremen, Bremen, Germany
| | - P Baumann
- Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland
| |
Collapse
|
26
|
Fekete S, Egberts K, Preissler T, Wewetzer C, Mehler-Wex C, Romanos M, Gerlach M. Therapeutic Drug Monitoring (TDM) of children and adolescents with tic disorders treated with tiapride. PHARMACOPSYCHIATRY 2017. [DOI: 10.1055/s-0037-1606421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- S Fekete
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| | - T Preissler
- Department of Child and Adolescent Psychiatry and Psychotherapy, Kepler University Clinics GmbH, Linz, Austria
| | - C Wewetzer
- Child and Adolescent Psychiatry and Psychotherapy, Clinics of City Cologne GmbH, Cologne, Germany
| | - C Mehler-Wex
- Adolescents and Young Adults, Hemera Private Hospital for Mental Health, Bad Kissingen, Germany
| | - M Romanos
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg Centre for Mental Healt, Würzburg, Germany
| |
Collapse
|
27
|
Abstract
Sleep related breathing disorders include central sleep apnea (CSA), obstructive sleep apnea (OSA), sleep-related hypoventilation, and sleep-related hypoxia. These disorders are frequent and growing in clinical relevance. The related chapter of the S3 guideline "Non-restorative sleep/Sleep disorders", published by the German Sleep Society (DGSM), has recently been updated in November 2016. Epidemiology, diagnostics, therapeutic procedures, and classification of sleep related disorders have been revised. Concerning epidemiology, a considerably higher mortality rate among pregnant women with OSA has been emphasized. With regards to diagnostics, the authors point out that respiratory polygraphy may be sufficient in diagnosing OSA, if a typical clinical condition is given. For CSA, recommendations were changed to diagnose CSA with low apnea rates present. Significant changes for treating CSA in patients with left ventricular dysfunction have been introduced. In addition, there is now to be differentiated between sleep-related hypoventilation and sleep-related hypoxaemia. Obesity hypoventilation syndrome is discussed in more detail. This article sums up and comments on the published changes.
Collapse
Affiliation(s)
- M Gerlach
- Medizinische Klinik, Agaplesion Bethesda Krankenhaus Wuppertal
| | - B Sanner
- Medizinische Klinik, Agaplesion Bethesda Krankenhaus Wuppertal
| |
Collapse
|
28
|
Gerlach M, Proksch AL, Unterer S, Speck S, Truyen U, Hartmann K. Efficacy of feline anti-parvovirus antibodies in the treatment of canine parvovirus infection. J Small Anim Pract 2017; 58:408-415. [PMID: 28369886 DOI: 10.1111/jsap.12676] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 01/17/2017] [Accepted: 01/20/2017] [Indexed: 12/01/2022]
Abstract
OBJECTIVE This prospective, randomised, placebo-controlled, double-blinded study aimed to evaluate efficacy of commercially available feline anti-parvovirus antibodies in dogs with canine parvovirus infection. METHODS First, cross-protection of feline panleukopenia virus antibodies against canine parvovirus was evaluated in vitro. In the subsequent prospective clinical trial, 31 dogs with clinical signs of canine parvovirus infection and a positive faecal canine parvovirus polymerase chain reaction were randomly assigned to a group receiving feline panleukopenia virus antibodies (n=15) or placebo (n=16). All dogs received additional routine treatment. Clinical signs, blood parameters, time to clinical recovery and mortality were compared between the groups. Serum antibody titres and quantitative faecal polymerase chain reaction were compared on days 0, 3, 7, and 14. RESULTS In vitro, canine parvovirus was fully neutralised by feline panleukopenia virus antibodies. There were no detected significant differences in clinical signs, time to clinical recovery, blood parameters, mortality, faecal virus load, or viral shedding between groups. Dogs in the placebo group showed a significant increase of serum antibody titres and a significant decrease of faecal virus load between day 14 and day 0, which was not detectable in dogs treated with feline panleukopenia virus antibodies. CLINICAL SIGNIFICANCE No significant beneficial effect of passively transferred feline anti-parvovirus antibodies in the used dosage regimen on the treatment of canine parvovirus infection was demonstrated.
Collapse
Affiliation(s)
- M Gerlach
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, 80539, Munich, Germany
| | - A L Proksch
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, 80539, Munich, Germany
| | - S Unterer
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, 80539, Munich, Germany
| | - S Speck
- Institute for Animal Hygiene and Veterinary Public Health, University of Leipzig, 04103, Leipzig, Germany
| | - U Truyen
- Institute for Animal Hygiene and Veterinary Public Health, University of Leipzig, 04103, Leipzig, Germany
| | - K Hartmann
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, 80539, Munich, Germany
| |
Collapse
|
29
|
Gerlach M, Abdul Wajid D, Hilfert L, Edelmann FT, Seidel-Morgenstern A, Hamel C. Impact of minor amounts of hydroperoxides on rhodium-catalyzed hydroformylation of long-chain olefins. Catal Sci Technol 2017. [DOI: 10.1039/c7cy00244k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The influence of varying hydroperoxide concentrations in olefin feeds was systematically investigated in rhodium-catalyzed hydroformylation using a diphosphite ligand.
Collapse
Affiliation(s)
- M. Gerlach
- Institute of Process Engineering
- Otto von Guericke University Magdeburg
- 39104 Magdeburg
- Germany
| | - D. Abdul Wajid
- Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg
- 39106 Magdeburg
- Germany
| | - L. Hilfert
- Institute of Chemistry
- Otto von Guericke University Magdeburg
- 39104 Magdeburg
- Germany
| | - F. T. Edelmann
- Institute of Chemistry
- Otto von Guericke University Magdeburg
- 39104 Magdeburg
- Germany
| | - A. Seidel-Morgenstern
- Institute of Process Engineering
- Otto von Guericke University Magdeburg
- 39104 Magdeburg
- Germany
- Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg
| | - C. Hamel
- Institute of Process Engineering
- Otto von Guericke University Magdeburg
- 39104 Magdeburg
- Germany
- Processing Engineering
| |
Collapse
|
30
|
Gerlach M, Kohls E, Lemberg M, Hamel C, Sadowski G, Seidel-Morgenstern A, Stein M. Vorhersage des Lösungsmitteleinflusses auf das Reaktionsgleichgewicht der Hydroformylierung von 1-Dodecen. CHEM-ING-TECH 2016. [DOI: 10.1002/cite.201650063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
31
|
Romanos M, Coghill D, Gerlach M, Becker K, Holtmann M, Döpfner M, Banaschewski T. Check and Double Check – the Cochrane review by Storebo et al. (2015) is indeed flawed. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2016; 44:336-337. [DOI: 10.1024/1422-4917/a000473] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- M. Romanos
- Zentrum für Psychische Gesundheit, Klinik für Kinder-und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| | - D. Coghill
- Departments of Paediatrics and Psychiatry, University of Melbourne, Melbourne, Australia
| | - M. Gerlach
- Zentrum für Psychische Gesundheit, Klinik für Kinder-und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| | - K. Becker
- Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Gießen und Marburg
| | - M. Holtmann
- Klinik für Kinder- und Jugendpsychiatrie, Psychotherapie und Psychosomatik, LWL-Universtitätsklinik Hamm der Ruhr-Universität Bochum
| | - M. Döpfner
- Ausbildungsinstitut für Kinder- und Jugendlichenpsychotherapie (AKiP) am Klinikum der Universität zu Köln
- Medizinische Fakultät, Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Universität zu Köln
| | - T. Banaschewski
- Zentralinstitut für Seelische Gesundheit Mannheim, Klinik für Psychiatrie und Psychotherapie des Kindes-und Jugendalters (KJP)
| |
Collapse
|
32
|
Abstract
One of the most celebrated findings in complex systems in the last decade is that different indexes y (e.g. patents) scale nonlinearly with the population x of the cities in which they appear, i.e. y∼x (β) ,β≠1. More recently, the generality of this finding has been questioned in studies that used new databases and different definitions of city boundaries. In this paper, we investigate the existence of nonlinear scaling, using a probabilistic framework in which fluctuations are accounted for explicitly. In particular, we show that this allows not only to (i) estimate β and confidence intervals, but also to (ii) quantify the evidence in favour of β≠1 and (iii) test the hypothesis that the observations are compatible with the nonlinear scaling. We employ this framework to compare five different models to 15 different datasets and we find that the answers to points (i)-(iii) crucially depend on the fluctuations contained in the data, on how they are modelled, and on the fact that the city sizes are heavy-tailed distributed.
Collapse
|
33
|
Banaschewski T, Gerlach M, Becker K, Holtmann M, Döpfner M, Romanos M. Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD. Z Kinder Jugendpsychiatr Psychother 2016; 44:307-14. [PMID: 27270192 DOI: 10.1024/1422-4917/a000433] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Objective A recent Cochrane review published by O. J. Storebo and colleagues (2015) raised substantial doubts about the benefit from stimulant medication with methylphenidate in the treatment of childhood ADHD due to the overall poor quality of studies. The systematic review thus contradicts all previous reviews and meta-analyses. Method We here detail various examples of errors, inconsistencies, and misinterpretations in the review which led to false results and inadequate conclusions. Results We demonstrate that the study selection is flawed and undertaken without sufficient scientific justification resulting in an underestimation of effect sizes, which, furthermore, are inadmissibly clinically interpreted. The methodology of the assessment of bias and quality is not objective and cannot be substantiated by the data. Conclusions Cochrane reviews lay claim to a high scientific quality and substantial relevance for evidence-based clinical decisions. The systematic review by Storebo and colleagues (2015) illustrates that, despite adhering to strict standards and high-quality protocols, even Cochrane works should be critically read and verified, sometimes with surprising results.
Collapse
Affiliation(s)
- T Banaschewski
- 1 Zentralinstitut für Seelische Gesundheit Mannheim, Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters (KJP)
| | - M Gerlach
- 2 Zentrum für Psychische Gesundheit, Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| | - K Becker
- 3 Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Gießen und Marburg
| | - M Holtmann
- 4 Klinik für Kinder- und Jugendpsychiatrie, Psychotherapie und Psychosomatik, LWL-Universtitätsklinik Hamm der Ruhr-Universität Bochum
| | - M Döpfner
- 5 Ausbildungsinstitut für Kinder- und Jugendlichenpsychotherapie (AKiP) am Klinikum der Universität zu Köln.,6 Medizinische Fakultät, Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Universität zu Köln
| | - M Romanos
- 2 Zentrum für Psychische Gesundheit, Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Würzburg
| |
Collapse
|
34
|
Egberts K, Dang SY, Fekete S, Wohkittel C, Albantakis L, Mehler-Wex M, Plener P, Wewetzer C, Romanos M, Gerlach M. Therapeutic Drug Monitoring in Children and Adolescents Treated with Second-Generation Antipsychotics in Daily Clinical Practice. Pharmacopsychiatry 2016. [DOI: 10.1055/s-0036-1582027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Huschmann FU, Gerlach M, Foerster R, Heine A, Hellmig M, Klebe G, Linnik J, Malecki PH, Metz A, Radeva N, Schiebel J, Sparta K, Steffien M, Uehlein M, Wilk P, Weiss MS, Mueller U. Crystallographic fragment-screening – results from the HZB-Marburg collaboration. Acta Crystallogr A Found Adv 2015. [DOI: 10.1107/s2053273315099386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
36
|
Egberts K, Dang SY, Plener P, Romanos M, Gerlach M. Pharmacovigilance in children and adolescents with psychiatric disorders. Pharmacopsychiatry 2014. [DOI: 10.1055/s-0034-1386812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Gerlach M. News from the field of pharmacovigilance. Pharmacopsychiatry 2014. [DOI: 10.1055/s-0034-1386810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
38
|
Egberts K, Preuss A, Wewetzer C, Unterecker S, Plener P, Gerlach M. Relation between dosage, serum concentration and therapeutic response of risperidone in children and adolescents with schizophrenic psychosis: data from a routine TDM-Service. Pharmacopsychiatry 2014. [DOI: 10.1055/s-0034-1386832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Dang SY, Jeutter V, Gerlach M, Romanos M, Taurines R, Egberts K. Aripiprazole induced extrapyramidal symptoms in two adolescents. Pharmacopsychiatry 2014. [DOI: 10.1055/s-0034-1386833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
40
|
Plum S, Helling S, Theiss C, Leite REP, May C, Jacob-Filho W, Eisenacher M, Kuhlmann K, Meyer HE, Riederer P, Grinberg LT, Gerlach M, Marcus K. Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis. J Proteomics 2013; 94:202-206. [PMID: 23917253 DOI: 10.1016/j.jprot.2013.07.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 06/26/2013] [Accepted: 07/15/2013] [Indexed: 10/26/2022]
Abstract
UNLABELLED This article gives a detailed description of a protocol using density gradient centrifugation for the enrichment of neuromelanin granules and synaptosomes from low amounts (≥0.15g) of human substantia nigra pars compacta tissue. This has a great advantage compared to already existing methods as it allows for the first time (i) a combined enrichment of neuromelanin granules and synaptosomes and (ii) just minimal amounts of tissue necessary to enable donor specific analysis. Individual specimens were classified as control or diseased according to clinical evaluation and neuropathological examination. For the enrichment of synaptosomes and neuromelanin granules from the same tissue sample density gradient centrifugations using Percoll® and Iodixanol were performed. The purity of resulting fractions was checked by transmission electron microscopy. We were able to establish a reproducible and easy to handle protocol combining two different density gradient centrifugations: using an Iodixanol gradient neuromelanin granules were enriched and in parallel, from the same sample, a fraction of synaptosomes with high purity using a Percoll® gradient was obtained. Our subfractionation strategy will enable a subsequent in depth proteomic characterization of neurodegenerative processes in the substantia nigra pars compacta in patients with Parkinson's disease and dementia with Lewy bodies compared to appropriate controls. BIOLOGICAL SIGNIFICANCE Key features of Parkinson's disease are the degeneration of dopaminergic neurons in the substantia nigra pars compacta, an associated loss of the brain pigment neuromelanin and a resulting impairment of the neuronal network. The accumulation of iron binding neuromelanin granules is age- and disease-dependent and disease specific alterations could affect the neuronal iron homeostasis leading to oxidative stress induced cell death. The focus of the described method is the analysis of neuromelanin granules as well as axonal cell-endings of nerve cells (synaptosomes) of individual donors (control and diseased). It is the basis for the identification of disease-relevant changes in the iron homeostasis and the generation of new insight into altered protein compositions or regulations which might lead to disturbed communications between nerve cells resulting in pathogenic processes.
Collapse
Affiliation(s)
- S Plum
- Department of Functional Proteomics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| | - S Helling
- Department of Functional Proteomics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| | - C Theiss
- Department of Cytology, Institute of Anatomy, Ruhr-Universität Bochum, Bochum, Germany.,Department of Anatomy and Molecular Embryology, Institute of Anatomy, Ruhr-Universität Bochum, Bochum, Germany
| | - R E P Leite
- Physiopathology in Aging Lab/Brazilian Aging Brain Study Group - LIM22, University of Sao Paulo Medical School, Sao Paulo, Brazil
| | - C May
- Department of Medical Proteomics/Bioanalytics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| | - W Jacob-Filho
- Physiopathology in Aging Lab, Geriatrics Discipline, University of Sao Paulo Medical School, Sao Paulo, Brazil
| | - M Eisenacher
- Department of Medical Proteomics/Bioanalytics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| | - K Kuhlmann
- Department of Medical Proteomics/Bioanalytics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| | - H E Meyer
- Department of Medical Proteomics/Bioanalytics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| | - P Riederer
- Clinical Neurochemistry, Clinic and Policlinic of Psychiatry, Psychosomatics and Psychotherapy, Bavarian Julius-Maximilians-Universität, Würzburg, Germany
| | - L T Grinberg
- Physiopathology in Aging Lab/Brazilian Aging Brain Study Group - LIM22, University of Sao Paulo Medical School, Sao Paulo, Brazil.,Department of Neurology, Memory and Aging Center, University of California, San Francisco, USA
| | - M Gerlach
- Laboratory of Clinical Neurobiology, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Bavarian Julius-Maximilians-Universität, Würzburg, Germany
| | - K Marcus
- Department of Functional Proteomics, Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
| |
Collapse
|
41
|
Buhr H, Büermann L, Gerlach M, Krumrey M, Rabus H. Measurement of the mass energy-absorption coefficient of air for x-rays in the range from 3 to 60 keV. Phys Med Biol 2012. [DOI: 10.1088/0031-9155/57/24/8231] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
Aicher B, Schuster T, Blumenstein L, Schmidt P, Irschik H, Jansen R, Mueller R, Guenther E, Gerlach M, Teifel M. 330 Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a LHRH Receptor Targeting Peptide Interfere with Cell Cycle Progression in Human Cancer Cell Lines and Suppress Tumor Growth in a LHRH Receptor Positive Ovarian Cancer Xenograft Model. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72128-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
43
|
Affiliation(s)
- W Kuhn
- Department of Neurology, St Josef-Hospital, Ruhr-University of Bochum, Gudrunstr. 56, 44791 Bochum, Germany
| | | | | | | |
Collapse
|
44
|
Foley P, Gerlach M, Youdim MB, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2012; 6:25-47. [PMID: 18591148 DOI: 10.1016/s1353-8020(99)00043-7] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/1998] [Revised: 06/29/1999] [Accepted: 06/29/1999] [Indexed: 11/16/2022]
Abstract
Monoamine oxidases play a central role in catecholamine catabolism in the central nervous system. The biochemical and pharmacological properties of inhibitors of the monoamine oxidase type B are reviewed. The evidence for biochemical activities distinct from their ability to inhibit MAO-B is discussed, including possible antioxidative and antiapoptotic activities of these agents. The significance of these properties for the pharmacological management of Parkinson's disease and the evidence for a neuroprotective effect of one such agent (selegiline) is also discussed.
Collapse
Affiliation(s)
- P Foley
- Clinical Neurochemistry, Department of Psychiatry, University of Würzburg, D-97080 Würzburg, Germany
| | | | | | | |
Collapse
|
45
|
Hansen D, Taurines R, Wewetzer C, Pfuhlmann B, Plener P, Mehler-Wex C, Gerlach M, Egberts K. Therapeutic drug monitoring (TDM) in children and adolescents treated with aripiprazole. Pharmacopsychiatry 2012. [DOI: 10.1055/s-0032-1326751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Kulpok C, Taurines R, Wewetzer C, Pfuhlmann B, Plener P, Mehler-Wex C, Gerlach M, Egberts K. Relation between dosage, serum concentration and therapeutic response of quetiapine in children and adolescents with different psychiatric disorders in clinical practice. Pharmacopsychiatry 2012. [DOI: 10.1055/s-0032-1326756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Gerlach M, Baas H, Jost W, Klucken J, Riederer P. Nutzen von Pharmakokinetik- und Pharmakogenetik-Wissen für die Parkinson-Therapie. Akt Neurol 2011. [DOI: 10.1055/s-0032-1304733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- M. Gerlach
- Universitätsklinikum für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universität Würzburg
| | - H. Baas
- Klinik für Neurologie, Klinikum Hanau
| | - W. Jost
- Deutsche Klinik für Diagnostik, Wiesbaden
| | - J. Klucken
- Abteilung für Molekulare Neurologie, Universitätsklinikum Erlangen
| | - P. Riederer
- Universitätsklinikum für Psychiatrie, Psychosomatik und Psychotherapie, Universität Würzburg
| |
Collapse
|
48
|
Koelch M, Pfalzer AK, Kliegl K, Rothenhöfer S, Ludolph AG, Fegert JM, Burger R, Mehler-Wex C, Stingl J, Taurines R, Egberts K, Gerlach M. Therapeutic drug monitoring of children and adolescents treated with fluoxetine. Pharmacopsychiatry 2011; 45:72-6. [PMID: 22086744 DOI: 10.1055/s-0031-1291294] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
INTRODUCTION Information about therapeutic serum levels of fluoxetine (FLX) and its major metabolite norfluoxetine (NORFLX) in children and adolescents is scarce. METHODS Therapeutic drug monitoring (TDM) of FLX was routinely performed in 71 subjects treated for a major depressive disorder (MDD) (10-60 mg/d FLX, median: 20 mg/d). Correlations between serum concentration and dosage, age, gender, smoking habits and adverse events were analysed. RESULTS Serum concentrations of the active moiety (FLX + NORFLX) ranged from 21 to 613 ng/mL (mean concentration of 213 ± 118 ng/mL, median: 185 ng/mL). High inter-individual variability in serum concentrations of the active moiety of FLX at each dosage level was observed and no relationship between serum concentration and clinical outcome was found. Apart from smoking, none of the factors tested had a significant eff ect on the serum concentration. DISCUSSION It was shown that serum concentrations of the active moiety of FLX in children and adolescents seem to be similar to those in adults, with a high level of inter-individual variation. The proportion of patients who showed benefits from treatment with a dose of 20 mg/d FLX was high.
Collapse
Affiliation(s)
- M Koelch
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Romanos M, Buske-Kirschbaum A, Fölster-Holst R, Gerlach M, Weidinger S, Schmitt J. Itches and scratches – is there a link between eczema, ADHD, sleep disruption and food hypersensitivity? Allergy 2011; 66:1407-9. [PMID: 21895691 DOI: 10.1111/j.1398-9995.2011.02705.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
50
|
Guenther M, Rauwolf T, Brüggemann B, Gerlach M, Wässnig NK, Christoph M, Braun MU, Strasser RH, Wunderlich C. Pre-hospital discharge testing after implantable cardioverter defibrillator implantation: A measure of safety or out of date? A retrospective analysis of 975 patients. Europace 2011; 14:217-23. [PMID: 21969525 DOI: 10.1093/europace/eur306] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Guenther
- Medical Clinic, Department of Internal Medicine and Cardiology, University of Technology Dresden, Fetscherstr. 76, 01307 Dresden, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|